BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 1997;26:122S-127S. [PMID: 9305676 DOI: 10.1002/hep.510260721] [Cited by in Crossref: 223] [Cited by in F6Publishing: 216] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Guilera M, Forns X, Torras X, Enríquez J, Coll S, Solà R, Morillas R, Planas R, Ampurdanès S, Soler M, Costa J, Sáiz JC, Sánchez-Tapias JM, Rodés J. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. J Hepatol 2000;33:135-41. [PMID: 10905597 DOI: 10.1016/s0168-8278(00)80170-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Marcellin P, Martinot M, Boyer N, Lévy S. TREATMENT OF HEPATITIS C PATIENTS WITH NORMAL AMINOTRANSFERASES LEVELS. Clinics in Liver Disease 1999;3:843-53. [DOI: 10.1016/s1089-3261(05)70242-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Ko JS, Choe YH, Kim EJ, Lee EH, Jang J, Seo JK. Interferon-α Treatment of Chronic Hepatitis C in Children with Hemophilia: . Journal of Pediatric Gastroenterology and Nutrition 2001;32:41-4. [DOI: 10.1097/00005176-200101000-00013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
4 Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36:S152-S160. [PMID: 12407589 DOI: 10.1053/jhep.2002.36381] [Cited by in Crossref: 25] [Cited by in F6Publishing: 76] [Article Influence: 1.3] [Reference Citation Analysis]
5 Desombere I, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G. Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. J Clin Microbiol. 2005;43:2590-2597. [PMID: 15956369 DOI: 10.1128/jcm.43.6.2590-2597.2005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
6 Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology. 2002;36:1259-1265. [PMID: 12395338 DOI: 10.1053/jhep.2002.36781] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 3.9] [Reference Citation Analysis]
7 Shahid M, Idrees M, Nasir B, Raja AJ, Raza SM, Amin I, Rasul A, Tayyab GU. Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients. Eur J Gastroenterol Hepatol 2014;26:788-94. [PMID: 24781355 DOI: 10.1097/MEG.0000000000000109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol. 1999;31 Suppl 1:237-243. [PMID: 10622595 DOI: 10.1016/s0168-8278(99)80409-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
9 Fabrizi F, Lunghi G, Aucella F, Mangano S, Barbisoni F, Bisegna S, Vigilante D, Limido A, Martin P. Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients. J Clin Microbiol. 2005;43:414-420. [PMID: 15635003 DOI: 10.1128/jcm.43.1.414-420.2005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
10 Hazari S, Acharya SK, Panda SK. Development and evaluation of a quantitative competitive reverse transcription polymerase chain reaction (RT-PCR) for hepatitis C virus RNA in serum using transcribed thio-RNA as internal control. Journal of Virological Methods 2004;116:45-54. [DOI: 10.1016/j.jviromet.2003.10.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
11 Buti M, Olive G, Stalgis C, Esteban R, Guardi J. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C. Dig Dis Sci 2000;45:685-9. [PMID: 10759235 DOI: 10.1023/a:1005479207106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Jesudian AB, de Jong YP, Jacobson IM. Emerging therapeutic targets for hepatitis C virus infection. Clin Gastroenterol Hepatol 2013;11:612-9.e1. [PMID: 23583900 DOI: 10.1016/j.cgh.2013.04.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
13 Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, Cosset FL, Folgori A, Lee DH, Brotman B, Prince AM. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol. 2008;82:10896-10905. [PMID: 18753204 DOI: 10.1128/jvi.01179-08] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
14 Battaglia AM, Hagmeyer KO. Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection. Ann Pharmacother 2000;34:487-94. [PMID: 10772437 DOI: 10.1345/aph.19183] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
15 Olaechea de Careaga B. Predictive factors for response to treatment of chronic hepatitis C. Annals of Hepatology 2006;5:S24-8. [DOI: 10.1016/s1665-2681(19)31965-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
16 Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999;30:526-530. [PMID: 10421663 DOI: 10.1002/hep.510300207] [Cited by in Crossref: 301] [Cited by in F6Publishing: 291] [Article Influence: 13.7] [Reference Citation Analysis]
17 Wang X, Liu F, Wei F, Ren H, Hu H. Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis. PLoS One 2014;9:e100128. [PMID: 24963667 DOI: 10.1371/journal.pone.0100128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
18 Trimoulet P, Halfon P, Pohier E, Khiri H, Chêne G, Fleury H. Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002;40:2031-6. [PMID: 12037059 DOI: 10.1128/JCM.40.6.2031-2036.2002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
19 Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol. 1999;30:192-198. [PMID: 10068095 DOI: 10.1016/s0168-8278(99)80061-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
20 Salmerón J, Ruiz-Extremera A, Torres C, Rodríguez-Ramos L, Lavín I, Quintero D, Palacios A. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver 1999;19:275-80. [PMID: 10459624 DOI: 10.1111/j.1478-3231.1999.tb00049.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lebray P, Zylberberg H, Hue S, Poulet B, Carnot F, Martin S, Chretien Y, Pol S, Caillat-zuckman S, Brechot C, Nalpas B. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 2004;11:175-82. [DOI: 10.1046/j.1365-2893.2003.00488.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
22 Inglesby TV, Rai R, Astemborski J, Gruskin L, Nelson KE, Vlahov D, Thomas DL. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999;29:590-6. [DOI: 10.1002/hep.510290219] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
23 Santagostino E, Rumi MG, Rivi M, Colombo M, Mannucci PM; Hepatitis Study Group of the Association of Italian Hemophilia Centers. Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. Blood 2002;99:1089-91. [PMID: 11807019 DOI: 10.1182/blood.v99.3.1089] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
24 Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:5. [PMID: 19152711 DOI: 10.1186/1471-230X-9-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
25 Ahmed F, Jacobson IM. Treatment of relapsers after combination therapy for chronic hepatitis C. Gastroenterol Clin North Am 2004;33:513-26, viii. [PMID: 15324941 DOI: 10.1016/j.gtc.2004.04.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
26 Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Fukuda Y. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000;96:4293-9. [DOI: 10.1182/blood.v96.13.4293] [Cited by in Crossref: 43] [Article Influence: 2.0] [Reference Citation Analysis]
27 Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. Journal of General Virology 2001;82:723-33. [DOI: 10.1099/0022-1317-82-4-723] [Cited by in Crossref: 174] [Cited by in F6Publishing: 162] [Article Influence: 8.7] [Reference Citation Analysis]
28 Abdelaty LN, Elnaggar AA, Said AA, Hussein RRS. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients. Curr Drug Saf 2020;15:53-60. [PMID: 31573893 DOI: 10.2174/1574886314666191001151314] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Pellicano R, Marietti G, Leone N, Arena V, Palmas F, Rizzetto M, Ponzetto A. Mixed cryoglobulinaemia associated with hepatitis C virus infection: a predictor factor for treatment with interferon? J Gastroenterol Hepatol 1999;14:1108-11. [PMID: 10574139 DOI: 10.1046/j.1440-1746.1999.02015.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
30 Malnick SD, Beergabel M, Lurie Y. Treatment of chronic hepatitis C virus infection. Ann Pharmacother 2000;34:1156-64. [PMID: 11054985 DOI: 10.1345/aph.10017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
31 Pár A, Telegdy L, Dalmi L, Müller E; Hungarian Viral Hepatitis Treatment Study Group. Therapy for chronic hepatitis C. J Physiol Paris 2001;95:399-405. [PMID: 11595466 DOI: 10.1016/s0928-4257(01)00054-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Koukoulis GK. Chronic hepatitis C: Grading, staging, and searching for reliable predictors of outcome. Human Pathology 2001;32:899-903. [DOI: 10.1053/hupa.2001.28441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
33 Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 1999;3:693-716, vii. [PMID: 11291246 DOI: 10.1016/s1089-3261(05)70234-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
34 Urquijo JJ, Diago M, Boadas J, Planas R, Solá R, del Olmo JA, Crespo J, Erdozaín JC, Antón MD, Arocena C, Suarez D, Giné J, Barrera JM, Gracia-samaniego J, Perez R, Dalmau B, Montoro M. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Annals of Hepatology 2013;12:30-5. [DOI: 10.1016/s1665-2681(19)31382-1] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hu K, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18. [DOI: 10.1046/j.1365-2893.2001.00253.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 2.7] [Reference Citation Analysis]
36 Gaglio PJ, Rodriguez-torres M, Herring R, Anand B, Box T, Rabinovitz M, Brown RS. Racial Differences in Response Rates to Consensus Interferon in HCV Infected Patients Naive to Previous Therapy: . Journal of Clinical Gastroenterology 2004;38:599-604. [DOI: 10.1097/00004836-200408000-00012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
37 Jorquera F, Almar M, Díaz-Golpe V, Olcóz JL, García-Fernández A, González-Gallego J. Impairment of metabolic function in chronic hepatitis C is related to factors associated with resistance to therapy. Am J Gastroenterol 2001;96:2456-61. [PMID: 11513190 DOI: 10.1111/j.1572-0241.2001.04053.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
38 Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29:1870-1875. [PMID: 10347132 DOI: 10.1002/hep.510290616] [Cited by in Crossref: 157] [Cited by in F6Publishing: 142] [Article Influence: 7.1] [Reference Citation Analysis]
39 Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2002;62:507-556. [PMID: 11827565 DOI: 10.2165/00003495-200262030-00009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
40 Yao Y, Liu M, Zang F, Yue M, Xia X, Feng Y, Fan H, Zhang Y, Huang P, Yu R. Association between human leucocyte antigen-DO polymorphisms and interferon/ribavirin treatment response in hepatitis C virus type 1 infection in Chinese population: a prospective study. BMJ Open 2018;8:e019406. [PMID: 29654010 DOI: 10.1136/bmjopen-2017-019406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
41 Nguyen NH, VuTien P, Garcia RT, Trinh H, Nguyen H, Nguyen K, Levitt B, Nguyen MH. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6. J Viral Hepat. 2010;17:691-697. [PMID: 20002562 DOI: 10.1111/j.1365-2893.2009.01226.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
42 Rajender Reddy K, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. Advanced Drug Delivery Reviews 2002;54:571-86. [DOI: 10.1016/s0169-409x(02)00028-5] [Cited by in Crossref: 175] [Cited by in F6Publishing: 27] [Article Influence: 9.2] [Reference Citation Analysis]
43 Ahmed A, Keeffe EB. OVERVIEW OF INTERFERON THERAPY FOR CHRONIC HEPATITIS C. Clinics in Liver Disease 1999;3:757-73. [DOI: 10.1016/s1089-3261(05)70237-3] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
44 Chow W, Boyer N, Pouteau M, Castelnau C, Martinot-peignoux M, Martins-amado V, Degos F, Maghinici C, Sinegre M, Benhamou J, Degott C, Erlinger S, Marcellin P. Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology 1998;27:1144-8. [DOI: 10.1002/hep.510270432] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
45 Sponseller CA, Ramrakhiani S. Treatment of hepatitis B and C following liver transplantation. Curr Gastroenterol Rep 2002;4:52-62. [DOI: 10.1007/s11894-002-0038-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Walkerpeach CR, Winkler M, Dubois DB, Pasloske BL. Ribonuclease-resistant RNA Controls (Armored RNA) for Reverse Transcription-PCR, Branched DNA, and Genotyping Assays for Hepatitis C Virus. Clinical Chemistry 1999;45:2079-85. [DOI: 10.1093/clinchem/45.12.2079] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
47 Calleja JL, Albillos A, Rossi I, Moreno R, Domper F, Martínez JL, Escartín P. Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response: TIME COURSE OF HCV-RNA DURING ANTI-VIRAL TREATMENT. Alimentary Pharmacology & Therapeutics 2001;15:241-9. [DOI: 10.1046/j.1365-2036.2001.00921.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Khalili M, Denham C, Perrillo R. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C. Am J Gastroenterol. 2000;95:1284-1289. [PMID: 10811340 DOI: 10.1111/j.1572-0241.2000.02025.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
49 Lalazar G, Ilan Y. Assessment of liver function in acute or chronic liver disease by the methacetin breath test: a tool for decision making in clinical hepatology. J Breath Res. 2009;3:047001. [PMID: 21386198 DOI: 10.1088/1752-7155/3/4/047001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
50 Kayali Z, Tan S, Shinkunas L, Voigt M, LaBrecque DR, Stapleton JT, Brown KE, Schmidt WN. Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans. J Viral Hepat 2007;14:11-21. [PMID: 17212639 DOI: 10.1111/j.1365-2893.2006.00764.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
51 Shaker OG, Eskander EF, Yahya SM, Mohamed MS, Abd-Rabou AA. Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients. Clin Chim Acta 2011;412:593-8. [PMID: 21159314 DOI: 10.1016/j.cca.2010.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
52 Mao H, Lu Z, Zhang H, Liu K, Zhao J, Jin G, Gu S, Yang M. Colorimetric oligonucleotide array for genotyping of hepatitis C virus based on the 5′ non-coding region. Clinica Chimica Acta 2008;388:22-7. [DOI: 10.1016/j.cca.2007.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
53 Reuman PD. Immunomodulators: . The Pediatric Infectious Disease Journal 2001;20:995-6. [DOI: 10.1097/00006454-200110000-00015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
54 Takahashi A, Iwasaki Y, Miyaike J, Taniguchi H, Shimomura H, Hanafusa T, Yumoto Y, Moriya A, Koide N, Tsuji T. Quantitative Analysis of p40/p46 and p69/p71 Forms of 2′,5′-Oligoadenylate Synthetase mRNA by Competitive PCR and Its Clinical Application. Clinical Chemistry 2002;48:1551-9. [DOI: 10.1093/clinchem/48.9.1551] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
55 Lee SS. Indicators and predictors of response to anti-viral therapy in chronic hepatitis C: REVIEW: RESPONSE PREDICTORS IN HEPATITIS C THERAPY. Alimentary Pharmacology & Therapeutics 2003;17:611-21. [DOI: 10.1046/j.1365-2036.2003.01463.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
56 Saracco G, Ciancio A, Ghisetti V, Rocca G, Cariti G, Andreoni M, Tabone M, Roffi L, Calleri G, Ballaré M. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group. Eur J Gastroenterol Hepatol. 2001;13:149-155. [PMID: 11246614 DOI: 10.1097/00042737-200102000-00010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
57 Kiang TKL, Wilby KJ, Ensom MHH. Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions. Clin Pharmacokinet 2013;52:487-510. [DOI: 10.1007/s40262-013-0053-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
58 Davis GL. Combination treatment with interferon and ribavirin for chronic hepatitis C. Clin Liver Dis. 1999;3:811-826. [PMID: 11291252 DOI: 10.1016/s1089-3261(05)70240-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
59 Shad JA, McHutchison JG. Current and future therapies of hepatitis C. Clin Liver Dis 2001;5:335-59. [PMID: 11385967 DOI: 10.1016/s1089-3261(05)70169-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
60 Kim YJ, Jang BK, Kim ES, Park KS, Cho KB, Chung WJ, Hwang JS. Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients. Korean J Hepatol. 2012;18:41-47. [PMID: 22511902 DOI: 10.3350/kjhep.2012.18.1.41] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
61 He Y, Katze MG. To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. Viral Immunol. 2002;15:95-119. [PMID: 11952150 DOI: 10.1089/088282402317340260] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 3.2] [Reference Citation Analysis]
62 Davis GL. Treatment of chronic hepatitis C: Improved combination therapy. Curr hepatitis rep 2003;2:40-6. [DOI: 10.1007/s11901-003-0013-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Taylor DR, Shi ST, Lai MM. Hepatitis C virus and interferon resistance. Microbes Infect 2000;2:1743-56. [PMID: 11137047 DOI: 10.1016/s1286-4579(00)01329-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
64 Yao GB, Fu XX, Tian GS, Xu DZ, Hao LJ, Huangfu YS, Su CX. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2000;15:1165-1170. [PMID: 11106097 DOI: 10.1046/j.1440-1746.2000.02307.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
65 Webster G, Barnes E, Brown D, Dusheiko G. HCV genotypes—role in pathogenesis of disease and response to therapy. Best Practice & Research Clinical Gastroenterology 2000;14:229-40. [DOI: 10.1053/bega.1999.0072] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
66 Mchutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-23. [DOI: 10.1053/gast.2000.19289] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 6.8] [Reference Citation Analysis]
67 Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Hollinger FB, Mullen KD, Pimstone N, Albert D, Gardner S. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group. Hepatology 1998;28:1411-5. [PMID: 9794929 DOI: 10.1002/hep.510280533] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.0] [Reference Citation Analysis]
68 Lurie Y, Nevens F, Aprosina ZG, Fedorova TA, Kalinin AV, Klimova EA, Ilan Y, Maevskaya MV, Warnes TW, Yuschuk ND, Hellstrand K, Gehlsen KR. A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. J Viral Hepat 2002;9:346-53. [PMID: 12225329 DOI: 10.1046/j.1365-2893.2002.00378.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
69 De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology. 2002;49:788-792. [PMID: 12063991 DOI: 10.1016/b978-044450986-4/50083-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Knapp S, Hennig BJ, Frodsham AJ, Zhang L, Hellier S, Wright M, Goldin R, Hill AV, Thomas HC, Thursz MR. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics. 2003;55:362-369. [PMID: 12942209 DOI: 10.1007/s00251-003-0594-5] [Cited by in Crossref: 116] [Cited by in F6Publishing: 109] [Article Influence: 6.4] [Reference Citation Analysis]
71 Fattovich G, Zagni I, Fornaciari G, Minola E, Fabris P, Boccia S, Giusti M, Abbati G, Felder M, Rovere P, Redaelli A, Tonon A, Montanari R, Paternoster C, Distasi M, Castagnetti E, Tositti G, Rizzo C, Suppressa S, Pantalena M, Lomonaco L, Scattolini C, Tagger A. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. J Viral Hepat 2003;10:111-7. [DOI: 10.1046/j.1365-2893.2003.00409.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
72 Lau JY, Fang JW, Mizokami M, Gish RG, Wright TL. Hepatitis C. In: Runge MS, Patterson C, editors. Principles of Molecular Medicine. Totowa: Humana Press; 2006. pp. 542-53. [DOI: 10.1007/978-1-59259-963-9_52] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Kosmacheva ED, Sergakova LM, At’kov OIu, Akchurin RS, Arabidze GG, Ataullakhanova DM. [Effects of surgical treatment on hypertrophy of the myocardium of the left ventricle in patients with symptomatic arterial hypertension]. Kardiologiia. 1991;31:25-28. [PMID: 1829771 DOI: 10.1002/jmv.21123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
74 Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409-414. [PMID: 16842444 DOI: 10.1111/j.1365-2893.2005.00707.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
75 Muga R, Sanvisens A, Fuster D, Tor J, Martínez E, Pérez-Hoyos S, Muñoz A. Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS One 2012;7:e46810. [PMID: 23056462 DOI: 10.1371/journal.pone.0046810] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
76 Ahmed F, Jacobson IM. Treatment of Relapsers after Combination Therapy for Chronic Hepatitis C. Infectious Disease Clinics of North America 2006;20:137-53. [DOI: 10.1016/j.idc.2006.01.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
77 Christie JM, Chapman RW. Combination therapy for chronic hepatitis C: interferon and ribavirin. Hospital Medicine 1999;60:357-61. [DOI: 10.12968/hosp.1999.60.5.1116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
78 Fujita N, Horiike S, Sugimoto R, Tanaka H, Iwasa M, Kobayashi Y, Hasegawa K, Ma N, Kawanishi S, Adachi Y. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med. 2007;42:353-362. [PMID: 17210448 DOI: 10.1016/j.freeradbiomed.2006.11.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 4.2] [Reference Citation Analysis]
79 Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, Preston FE, Watson HG, Wilde JT, Winter M; Transfusion Transmitted Infection Working Party of the UK Haemophilia Centre Directors Organization. Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001;7:339-45. [PMID: 11442636 DOI: 10.1046/j.1365-2516.2001.00527.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
80 Doglio A, Laffont C, Caroli-bosc FX, Rochet P, Lefebvre J. Second Generation of the Automated Cobas Amplicor HCV Assay Improves Sensitivity of Hepatitis C Virus RNA Detection and Yields Results That Are More Clinically Relevant. J Clin Microbiol 1999;37:1567-9. [DOI: 10.1128/jcm.37.5.1567-1569.1999] [Cited by in Crossref: 67] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
81 Fabris C, Soardo G, Falleti E, Toniutto P, Vitulli D, Federico E, Forno MD, Mattiuzzo M, Gonano F, Pirisi M. Relationship Among Hepatic Inflammatory Changes, Circulating Levels of Cytokines, and Response to IFN-α in Chronic Hepatitis C. Journal of Interferon & Cytokine Research 1998;18:705-9. [DOI: 10.1089/jir.1998.18.705] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
82 Davis GL, Beck JR, Farrell G, Poynard T. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: a decision analysis. J Viral Hepat 1998;5:313-21. [DOI: 10.1046/j.1365-2893.1998.00119.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
83 Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol. 2000;95:740-747. [PMID: 10710068 DOI: 10.1111/j.1572-0241.2000.01854.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 85] [Article Influence: 3.6] [Reference Citation Analysis]
84 Schröter M, Zöllner B, Schäfer P, Landt O, Lass U, Laufs R, Feucht HH. Genotyping of hepatitis C virus types 1, 2, 3, and 4 by a one-step LightCycler method using three different pairs of hybridization probes. J Clin Microbiol 2002;40:2046-50. [PMID: 12037062 DOI: 10.1128/JCM.40.6.2046-2050.2002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
85 Goldsmith J, Hauser P. Psychiatric Issues in Patients with Hepatitis C. Psychiatric Annals 2003;33:357-60. [DOI: 10.3928/0048-5713-20030601-04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
86 Rong X, Lu L, Wang J, Xiong H, Huang J, Chen J, Huang K, Xu R, Wang M, Zhang X. Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains. PLoS One. 2012;7:e52467. [PMID: 23285053 DOI: 10.1371/journal.pone.0052467] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
87 Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children: . The Pediatric Infectious Disease Journal 2000;19:23-30. [DOI: 10.1097/00006454-200001000-00006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
88 Eskander EF, Abd-Rabou AA, Mohamed MS, Yahya SM, Shaker OG. Does HCV Patients Who Have BCL2 43Ala Genotype and Normal GH1 Levels Can Achieve Response to IFN Based Therapy? Indian J Clin Biochem 2012;27:344-50. [PMID: 24082458 DOI: 10.1007/s12291-012-0219-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
89 Nguyen NH, Vutien P, Trinh HN, Garcia RT, Nguyen LH, Nguyen HA, Nguyen KK, Nguyen MH. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol Int. 2010;4:523-529. [PMID: 20827411 DOI: 10.1007/s12072-010-9181-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
90 Costa MA, Schiff ER. Hepatitis C. Curr Treat Options Gastro 1999;2:481-9. [DOI: 10.1007/s11938-999-0052-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
91 Ripoli M, Pazienza V. Impact of HCV genetic differences on pathobiology of disease. Expert Rev Anti Infect Ther 2011;9:747-59. [PMID: 21905784 DOI: 10.1586/eri.11.94] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
92 Yang J, Nugroho AS, Yamauchi K, Yoshioka K, Zheng J, Wang K, Kato K, Kuroyanagi S, Iwata A. Efficacy of interferon treatment for chronic hepatitis C predicted by feature subset selection and support vector machine. J Med Syst 2007;31:117-23. [PMID: 17489504 DOI: 10.1007/s10916-006-9046-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
93 Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, Gutekunst K, Rosenstraus M. Improved Version 2.0 Qualitative and Quantitative AMPLICOR Reverse Transcription-PCR Tests for Hepatitis C Virus RNA: Calibration to International Units, Enhanced Genotype Reactivity, and Performance Characteristics. J Clin Microbiol 2000;38:4171-9. [DOI: 10.1128/jcm.38.11.4171-4179.2000] [Cited by in Crossref: 118] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
94 Siman-Tov DD, Zemel R, Tur Kaspa R, Gershoni JM. The use of epitope arrays in immunodiagnosis of infectious disease: hepatitis C virus, a case study. Anal Biochem 2013;432:63-70. [PMID: 23017878 DOI: 10.1016/j.ab.2012.09.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
95 Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, Locarnini S. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol. 2002;97:982-987. [PMID: 12003436 DOI: 10.1111/j.1572-0241.2002.05550.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
96 Siu L, Foont J, Wands JR. Hepatitis C virus and alcohol. Semin Liver Dis 2009;29:188-99. [PMID: 19387918 DOI: 10.1055/s-0029-1214374] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
97 Amanzada A, Goralczyk A, Moriconi F, Blaschke M, Schaefer IM, van Thiel D, Mihm S, Ramadori G. Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy. Dig Dis Sci 2011;56:3296-304. [PMID: 21994136 DOI: 10.1007/s10620-011-1933-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
98 Gonzaga RM, Rodart IF, Reis MG, Ramalho Neto CE, Silva DW. Distribution of Hepatitis C virus (HCV) genotypes in seropositive patients in the state of Alagoas, Brazil. Braz J Microbiol 2008;39:644-7. [PMID: 24031281 DOI: 10.1590/S1517-83822008000400008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
99 Jeong S, Kawakami Y, Kitamoto M, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Uka K, Takaki S, Kodama H. Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy. J Gastroenterol Hepatol. 2008;23:541-545. [PMID: 18397484 DOI: 10.1111/j.1440-1746.2008.05356.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
100 Iacovazzi PA, Cozzolongo R, Lanzillotta E, Frisullo S, Guerra V, Correale M. Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients. Immunopharmacol Immunotoxicol 2008;30:687-700. [PMID: 18720164 DOI: 10.1080/08923970802278177] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
101 Davis GL. Current therapy for chronic hepatitis C. Gastroenterology. 2000;118:S104-S114. [PMID: 10868901 DOI: 10.1016/s0016-5085(00)70009-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
102 Strader DB, Seeff LB. A brief history of the treatment of viral hepatitis C. Clin Liver Dis. 2012;1:6-11. [PMID: 31186837 DOI: 10.1002/cld.1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
103 Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol. 1999;7:402-410. [PMID: 10498948 DOI: 10.1016/S0966-842X(99)01590-5] [Cited by in Crossref: 96] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
104 Kumar R, Kumar S, Sharma BC, Singh J, Sarin SK. Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study. J Gastroenterol Hepatol 2005;20:527-35. [PMID: 15836700 DOI: 10.1111/j.1440-1746.2005.03760.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
105 Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;50:1142-1154. [PMID: 19395111 DOI: 10.1016/j.jhep.2009.01.019] [Cited by in Crossref: 148] [Cited by in F6Publishing: 147] [Article Influence: 12.3] [Reference Citation Analysis]
106 Malik AH, Kumar KS, Malet PF, Ostapowicz G, Adams G, Wood M, Yarbrough K, Jones A, Lee WM. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin in chronic hepatitis C patients who have not responded to standard dose interferon. Aliment Pharmacol Ther. 2002;16:381-388. [PMID: 11876690 DOI: 10.1046/j.1365-2036.2002.01201.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
107 Lamb MW, Martin NE. Weight-Based versus Fixed Dosing of Peginterferon (40kDa) Alfa-2a. Ann Pharmacother 2002;36:933-5. [DOI: 10.1177/106002800203600501] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
108 Taylor DR, Tian B, Romano PR, Hinnebusch AG, Lai MM, Mathews MB. Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain. J Virol. 2001;75:1265-1273. [PMID: 11152499 DOI: 10.1128/jvi.75.3.1265-1273.2001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
109 Fargion S, Bruno S, Borzio M, Battezzati PM, Bissoli F, Ceriani R, Orlandi A, Maraschi A, Chiesa A, Morini L. Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. J Hepatol. 2003;38:499-505. [PMID: 12663243 DOI: 10.1016/s0168-8278(02)00388-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
110 Ilan Y. A fourth dimension in decision making in hepatology. Hepatol Res 2010;40:1143-54. [PMID: 20973886 DOI: 10.1111/j.1872-034X.2010.00737.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
111 Wang C, Mo L, Lin R, Kuo J, Chang K, Wu J. Artificial Neural Network Model Is Superior to Logistic Regression Model in Predicting Treatment Outcomes of Interferon-Based Combination Therapy in Patients with Chronic Hepatitis C. Intervirology 2008;51:14-20. [DOI: 10.1159/000118791] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
112 Neuman MG, Blendis LM, Shear NH, Malkiewicz IM, Ibrahim A, Katz GG, Sapir D, Halpern Z, Brill S, Peretz H, Magazinik S, Konikoff FM. Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate. Clin Biochem 2001;34:183-8. [PMID: 11408015 DOI: 10.1016/s0009-9120(01)00213-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
113 Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708. [PMID: 15185312 DOI: 10.1002/hep.20212] [Cited by in Crossref: 211] [Cited by in F6Publishing: 181] [Article Influence: 12.4] [Reference Citation Analysis]
114 Zhou DX, Tang JW, Chu IM, Cheung JL, Tang NL, Tam JS, Chan PK. Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong. J Med Virol. 2006;78:574-581. [PMID: 16555294 DOI: 10.1002/jmv.20578] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
115 Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001;96:3142-3146. [PMID: 11721762 DOI: 10.1111/j.1572-0241.2001.05268.x] [Cited by in Crossref: 186] [Cited by in F6Publishing: 173] [Article Influence: 9.8] [Reference Citation Analysis]
116 Natov SN, Pereira BJG. Management of Hepatitis C Infection in Renal Transplant Recipients: Management of HCV in Renal Transplant Patients. American Journal of Transplantation 2002;2:483-90. [DOI: 10.1034/j.1600-6143.2002.20601.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
117 Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. Hepatology 2000;32:889-96. [PMID: 11050035 DOI: 10.1053/jhep.2000.19150] [Cited by in Crossref: 96] [Cited by in F6Publishing: 95] [Article Influence: 4.6] [Reference Citation Analysis]
118 Zhang XX, Zhang SY, Liu J, Lu ZM, Wang Y. Expression of hepatitis C virus hypervariable region 1 and its clinical significance. World J Gastroenterol 2003; 9(5): 1003-1007 [PMID: 12717846 DOI: 10.3748/wjg.v9.i5.1003] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
119 Fang JW, Chow V, Lau JY. VIROLOGY OF HEPATITIS C VIRUS. Clinics in Liver Disease 1997;1:493-514. [DOI: 10.1016/s1089-3261(05)70317-2] [Cited by in Crossref: 18] [Article Influence: 0.8] [Reference Citation Analysis]
120 Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 2001;8:70-7. [DOI: 10.1046/j.1365-2893.2001.00268.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
121 Thomopoulos KC, Theocharis GJ, Tsamantas AC, Siagris D, Dimitropoulou D, Gogos CA, Labropoulou-Karatza C. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2005;17:149-153. [PMID: 15674091 DOI: 10.1097/00042737-200502000-00004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
122 Zeniya M, Toda G. Case selection for interferon treatment of hepatitis C. J Gastroenterol Hepatol 2000;15:E117-22. [DOI: 10.1046/j.1440-1746.2000.02111.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
123 Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol. 2000;30:125-143. [PMID: 10730918 DOI: 10.1097/00004836-200003000-00005] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 4.1] [Reference Citation Analysis]
124 Idrees M. Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. J Virol Methods. 2008;150:50-56. [PMID: 18423633 DOI: 10.1016/j.jviromet.2008.03.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
125 Shou WZ, Bu H, Addison T, Jiang X, Naidong W. Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum. Journal of Pharmaceutical and Biomedical Analysis 2002;29:83-94. [DOI: 10.1016/s0731-7085(02)00003-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 2] [Article Influence: 2.8] [Reference Citation Analysis]
126 Lirussi F, Beccarello A, Bortolato L, Morselli-Labate AM, Crovatto M, Ceselli S, Santini G, Crepaldi G. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver. 1999;19:381-388. [PMID: 10533795 DOI: 10.1111/j.1478-3231.1999.tb00066.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
127 Bourlière M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, Benali S, Boustière C, Perrier H, Jullien M, Lambot G, Loyer R, LeBars O, Daniel R, Khiri H, Halfon P. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat 2002;9:62-70. [PMID: 11851904 DOI: 10.1046/j.1365-2893.2002.00319.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 3.5] [Reference Citation Analysis]
128 Suzuki K, Ohkoshi S, Yano M, Ichida T, Takimoto M, Naitoh A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T, Aoyagi Y. Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis: Biochemical remission after the interferon treatment. Liver International 2003;23:143-7. [DOI: 10.1034/j.1600-0676.2003.00822.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
129 Ke PY, Chen SSL. Autophagy in hepatitis C virus-host interactions: Potential roles and therapeutic targets for liver-associated diseases. World J Gastroenterol 2014; 20(19): 5773-5793 [PMID: 24914338 DOI: 10.3748/wjg.v20.i19.5773] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
130 Oh IS, Won JW, Kim HJ, Lee HW. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. Korean J Intern Med 2017;32:1010-7. [PMID: 28797159 DOI: 10.3904/kjim.2016.405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
131 Davis GL. TREATMENT OF ACUTE AND CHRONIC HEPATITIS C. Clinics in Liver Disease 1997;1:615-30. [DOI: 10.1016/s1089-3261(05)70325-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Badawi MM, Mohammed AA, Mohammed MS, Saeed MM, Ali EY, Khalil A. A Diagnostic Laboratory-Based Study on Frequency and Distribution of Viral Hepatitis B and C Among Sudanese. Open Virol J. 2017;11:98-107. [PMID: 29399232 DOI: 10.2174/1874357901711010098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Min AD, Jones JL, Esposito S, Lebovics E, Jacobson IM, Klion FM, Goldman IS, Geders JM, Tobias H, Bodian C. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am J Gastroenterol. 2001;96:1143-1149. [PMID: 11316161 DOI: 10.1111/j.1572-0241.2001.03692.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
134 Uyama H, Nakamura H, Hayashi E, Ogawa H, Enomoto H, Yoshida K, Okuda Y, Yamamoto M, Hada T, Hayashi N. Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. Hepatology Research 2007;37:325-30. [DOI: 10.1111/j.1872-034x.2007.00044.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
135 Tamalet C, Colson P, Tissot-dupont H, Henry M, Tourres C, Tivoli N, Botta D, Ravaux I, Poizot-martin I, Yahi N. Genomic and phylogenetic analysis of hepatitis C virus isolates: A survey of 535 strains circulating in southern France. J Med Virol 2003;71:391-8. [DOI: 10.1002/jmv.10505] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
136 Martinot-Peignoux M, Le Breton V, Fritsch S, Le Guludec G, Labouret N, Keller F, Marcellin P. Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays. J Clin Microbiol 2000;38:2722-5. [PMID: 10878070 DOI: 10.1128/JCM.38.7.2722-2725.2000] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
137 Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, Pockros PJ, Blatt LM, Conrad A, McHutchison JG. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol. 2003;18:253-257. [PMID: 12603524 DOI: 10.1046/j.1440-1746.2003.02930.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.1] [Reference Citation Analysis]
138 Sułowicz W, Radziszewski A, Chowaniec E. Hepatitis C virus infection in dialysis patients. Hemodialysis Int 2007;11:286-95. [DOI: 10.1111/j.1542-4758.2007.00181.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
139 Melian EB, Plosker GL. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001;61:1661-91. [PMID: 11577799 DOI: 10.2165/00003495-200161110-00009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
140 Chan AH, Partovi N, Ensom MH. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review. Ann Pharmacother 2009;43:2044-63. [PMID: 19920162 DOI: 10.1345/aph.1M225] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
141 González-Peralta RP, Galasso GJ, Poynard T, Schalm S, Thomas HC, Wright TL. Summary of the first international symposium on viral hepatitis. Antiviral Res 1999;42:77-96. [PMID: 10389652 DOI: 10.1016/s0166-3542(99)00023-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Cotler SJ, Jensen DM. TREATMENT OF HEPATITIS C VIRUS AND HIV CO-INFECTIONS. Clinics in Liver Disease 2001;5:1045-61. [DOI: 10.1016/s1089-3261(05)70208-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
143 Esquivel F, Albillos A, Carrión F, Prieto A, Reyes E, Martínez-Martin B, Calleja JL, Cacho G, Alvarez-Mon M. Relationship between response to interferon-alpha and function of peripheral blood mononuclear cells in chronic hepatitis C patients. Dig Dis Sci. 2002;47:2154-2162. [PMID: 12395886 DOI: 10.1023/a:1020162605925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
144 Chang M, Sung K, Sheen I, Lin S, Yeh C. A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C. Journal of Viral Hepatitis 2009;16:359-66. [DOI: 10.1111/j.1365-2893.2009.01090.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
145 Lo Iacono O, Castro A, Diago M, Moreno JA, Fernandez-Bermejo M, Vega P, García V, Carbonell P, Sanz P, Borque MJ, García-Buey L, García-Monzón C, Pedreira J, Moreno-Otero R. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Aliment Pharmacol Ther 2000;14:463-9. [PMID: 10759626 DOI: 10.1046/j.1365-2036.2000.00713.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
146 Fabris, Tositti, Negro, Marranconi, Infantolino, Rassu, De Lalla. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients: INTERFERON PLUS KETOPROFEN IN CHRONIC HEPATITIS C. Alimentary Pharmacology & Therapeutics 1999;13:1329-34. [DOI: 10.1046/j.1365-2036.1999.00613.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
147 Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrère JJ, Pawlotsky JM, De Micco P, Laperche S. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol. 2007;45:1140-1145. [PMID: 17251399 DOI: 10.1128/jcm.01982-06] [Cited by in Crossref: 85] [Cited by in F6Publishing: 30] [Article Influence: 6.1] [Reference Citation Analysis]
148 Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, Hauser P. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett. 2004;365:87-91. [PMID: 15245784 DOI: 10.1016/j.neulet.2004.04.058] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
149 Mawatari H, Yoneda M, Fujita K, Nozaki Y, Shinohara Y, Sasaki H, Iida H, Takahashi H, Inamori M, Abe Y, Kobayashi N, Kubota K, Kirikoshi H, Nakajima A, Saito S. Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. Journal of Viral Hepatitis 2010;17:274-9. [DOI: 10.1111/j.1365-2893.2009.01179.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
150 Fabrizi F, Lunghi G, Poordad FF, Martin P. Genetic variability of hepatitis C virus in dialysis: the implications. Int J Artif Organs 2002;25:1034-48. [PMID: 12487391 DOI: 10.1177/039139880202501102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171. [PMID: 15057920 DOI: 10.1002/hep.20119] [Cited by in Crossref: 1226] [Cited by in F6Publishing: 1119] [Article Influence: 72.1] [Reference Citation Analysis]
152 Halfon P, Cacoub P. Quantification virale du virus de l'hépatite C : présent et avenir. La Revue de Médecine Interne 2000;21:174-81. [DOI: 10.1016/s0248-8663(00)88247-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
153 Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies. Dig Dis Sci 2003;48:1654-7. [PMID: 12924664 DOI: 10.1023/a:1024796630509] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Erali M, Ashwood ER, Hillyard DR. Performance characteristics of the COBAS AMPLICOR hepatitis C virus MONITOR Test, version 2.0. Am J Clin Pathol 2000;114:180-7. [PMID: 10941332 DOI: 10.1309/KAJF-DL9G-0PNB-0FYH] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
155 Stravitz RT, Ilan Y. Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic? Liver Int 2017;37:328-36. [DOI: 10.1111/liv.13268] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
156 Katayama K, Kasahara A, Sasaki Y, Kashiwagi T, Naito M, Masuzawa M, Katoh M, Yoshihara H, Kamada T, Mukuda T. Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance. J Viral Hepat. 2001;8:180-185. [PMID: 11380795 DOI: 10.1046/j.1365-2893.2001.00274.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
157 Mckechnie VM, Mills PR, Mccruden EA. The NS5a gene of hepatitis C virus in patients treated with interferon-? J Med Virol 2000;60:367-78. [DOI: 10.1002/(sici)1096-9071(200004)60:4<367::aid-jmv2>3.0.co;2-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
158 Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA. 2002;99:3081-3086. [PMID: 11880647 DOI: 10.1073/pnas.052712599] [Cited by in Crossref: 144] [Cited by in F6Publishing: 148] [Article Influence: 7.6] [Reference Citation Analysis]
159 Laperche S, Lunel F, Izopet J, Alain S, Dény P, Duverlie G, Gaudy C, Pawlotsky JM, Plantier JC, Pozzetto B, Thibault V, Tosetti F, Lefrère JJ. Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 2005;43:733-9. [PMID: 15695672 DOI: 10.1128/JCM.43.2.733-739.2005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
160 Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, Niu WF, Jeng J, Liu CJ, Lai MY, Chen PJ. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA. 2011;108:3719-3724. [PMID: 21321200 DOI: 10.1073/pnas.1100349108] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.9] [Reference Citation Analysis]
161 Owens G, Emons MF, Christian-herman J, Lawless G. Current Trends in Pharmacy Benefit Designs: A Threat to Disease Management in Chronic Complex Diseases. Disease Management 2007;10:74-82. [DOI: 10.1089/dis.2006.638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
162 Tarantino G, Sorrentino P, Conca P, Perrella A, Ragucci P, Perrella O. Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. Liver Int 2003;23:413-9. [PMID: 14986815 DOI: 10.1111/j.1478-3231.2003.00871.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
163 Planas R, Quer JC, Enríquez J, Barrera JM, Dalmau B, Casanovas T, Viver JM, Torres M, Boadas J, Solà R, Durández R, Richart C, Bruguera M. [Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study]. Med Clin (Barc) 2002;118:641-4. [PMID: 12028899 DOI: 10.1016/s0025-7753(02)72483-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
164 Ahmed A, Keeffe E. Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference. Journal of Gastroenterology and Hepatology 2009;14:S12-8. [DOI: 10.1046/j.1440-1746.1999.01875.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
165 Eskander EF, Abd-Rabou AA, Yahya SM, Shaker OG, Mohamed MS. Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients? Clin Biochem 2012;45:3-6. [PMID: 21933670 DOI: 10.1016/j.clinbiochem.2011.08.1145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
166 Ikeda F, Shimomura H, Miyake M, Fujioka SI, Itoh M, Takahashi A, Iwasaki Y, Sakaguchi K, Yamamoto K, Higashi T, Tsuji T. Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta. J Interferon Cytokine Res 2000;20:831-6. [PMID: 11032403 DOI: 10.1089/10799900050151102] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
167 Giguere A, Anas A, Nasser T, Hassan M, Ahmed U, Beejay N, Nouh M, Khalowf M, Saleh A, Khan A, Attia M, El-azab G. Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: A single United Arab Emirates center experience. European Journal of Internal Medicine 2011;22:582-6. [DOI: 10.1016/j.ejim.2011.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
168 Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt JJ, Selves J, Barange K, Puel J, Pascal JP. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc). Hepatology 1998;28:1680-6. [PMID: 9828235 DOI: 10.1002/hep.510280631] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
169 Davis GL, Krawczynski K, Szabo G. Hepatitis C Virus Infection—Pathobiology and Implications for New Therapeutic Options. Dig Dis Sci 2007;52:857-75. [DOI: 10.1007/s10620-006-9484-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
170 Schmidt WN, Wu P, Brashear D, Klinzman D, Phillips MJ, LaBrecque DR, Stapleton JT. Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells. Hepatology. 1998;28:1110-1116. [PMID: 9755250 DOI: 10.1002/hep.510280428] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
171 Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000;13:223-35. [PMID: 10755999 DOI: 10.1128/CMR.13.2.223] [Cited by in Crossref: 153] [Cited by in F6Publishing: 159] [Article Influence: 7.3] [Reference Citation Analysis]
172 Rossini A, Artini M, Levrero M, Almerighi C, Massari M, Biasi L, Radaeli E, Cariani E. Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules. Dig Dis Sci 2001;46:2389-95. [PMID: 11713941 DOI: 10.1023/a:1012303315214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
173 Loayza T. Hepatitis C. J Am Acad Nurse Pract 1999;11:407-12; quiz 413-5. [PMID: 10690091 DOI: 10.1111/j.1745-7599.1999.tb00599.x] [Reference Citation Analysis]
174 Sáez-López A, Agüero-Balbín J. [Hepatitis B and C virus antiviral resistance]. Enferm Infecc Microbiol Clin 2006;24:576-84. [PMID: 17125678 DOI: 10.1157/13093879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Yokozaki S, Takamatsu J, Nakano I, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Fukuda Y. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000;96:4293-9. [DOI: 10.1182/blood.v96.13.4293.h8004293_4293_4299] [Cited by in Crossref: 10] [Article Influence: 0.5] [Reference Citation Analysis]
176 Mirza S, Siddiqui AR, Hamid S, Umar M, Bashir S. Extent of liver inflammation in predicting response to interferon α & Ribavirin in chronic hepatitis C patients: a cohort study. BMC Gastroenterol 2012;12:71. [PMID: 22697612 DOI: 10.1186/1471-230X-12-71] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
177 Ruiz-moreno M, Leal-orozco A, Millàn A. Hepatitis C virus infection in children. Journal of Hepatology 1999;31:124-9. [DOI: 10.1016/s0168-8278(99)80388-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
178 Stańczak JJ, Opoka-kegler J, Czerwionka-szaflarska M, Karczewska K, Woíakowska-gesicka T, Horban A. Distribution of hepatitis C virus genotypes in Poland. Journal of Hepatology 1999;31:574. [DOI: 10.1016/s0168-8278(99)80055-5] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
179 López-labrador F, Ampurdanès S, Giménez-barcons M, Guilera M, Costa J, Jiménez de Anta MT, Sánchez-tapias JM, Rodés J, Sáiz J. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b interferon: Relationship of the Genomic Complexity of Hepatitis C Virus With Liver Disease Severity and Response to Interferon in Patients With Chronic HCV Genoty. Hepatology 1999;29:897-903. [DOI: 10.1002/hep.510290306] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 3.6] [Reference Citation Analysis]
180 Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, Lin YH. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 2012; 18(8): 746-753 [PMID: 22371634 DOI: 10.3748/wjg.v18.i8.746] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
181 Diego JM, Roth D. Treatment of hepatites C infection in patients withrenal disease: . Current Opinion in Nephrology and Hypertension 1998;7:557-62. [DOI: 10.1097/00041552-199809000-00012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
182 Einav S, Sobol HD, Gehrig E, Glenn JS. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis 2010;202:65-74. [PMID: 20486856 DOI: 10.1086/653080] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
183 Ilina EN, Malakhova MV, Generozov EV, Nikolaev EN, Govorun VM. Matrix-assisted laser desorption ionization-time of flight (mass spectrometry) for hepatitis C virus genotyping. J Clin Microbiol 2005;43:2810-5. [PMID: 15956402 DOI: 10.1128/JCM.43.6.2810-2815.2005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
184 McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis. 2000;2:166-185. [PMID: 11429029 DOI: 10.1034/j.1399-3062.2000.020403.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
185 Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010;24:597-602. [PMID: 21037988 DOI: 10.1155/2010/717845] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
186 Brook MG. European guideline for the management of hepatitis B and C virus infections. Int J STD AIDS 2001;12:48-57. [DOI: 10.1258/0956462011923930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
187 Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, Bissoli F, Ceriani R, Ballarè M, Massari M. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol. 2002;97:1204-1210. [PMID: 12014729 DOI: 10.1111/j.1572-0241.2002.05705.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 18] [Article Influence: 0.2] [Reference Citation Analysis]
188 Bressler B. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44. [DOI: 10.1053/jhep.2003.50350] [Cited by in Crossref: 254] [Cited by in F6Publishing: 243] [Article Influence: 14.1] [Reference Citation Analysis]
189 Bortolotti F, Resti M, Marcellini M, Giacchino R, Verucchi G, Nebbia G, Zancan L, Marazzi MG, Barbera C, Maccabruni A, Zuin G, Maggiore G, Balli F, Vajro P, Lepore L, Molesini M, Guido M, Bartolacci S, Noventa F. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut 2005;54:852-7. [PMID: 15888796 DOI: 10.1136/gut.2004.053744] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
190 Rehan HS, Manak S, Yadav M. Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C. Indian J Pharmacol 2014;46:490-2. [PMID: 25298576 DOI: 10.4103/0253-7613.140578] [Reference Citation Analysis]
191 Ross RS, Viazov SO, Holtzer CD, Beyou A, Monnet A, Mazure C, Roggendorf M. Genotyping of Hepatitis C Virus Isolates using CLIP Sequencing. J Clin Microbiol 2000;38:3581-4. [DOI: 10.1128/jcm.38.10.3581-3584.2000] [Cited by in Crossref: 54] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
192 McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol. 2000;15:945-951. [PMID: 11022838 DOI: 10.1046/j.1440-1746.2000.02233.x] [Cited by in Crossref: 160] [Cited by in F6Publishing: 149] [Article Influence: 8.0] [Reference Citation Analysis]
193 Shedlofsky SI. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question? Am J Gastroenterology 2002;97:1093-6. [DOI: 10.1111/j.1572-0241.2002.05701.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
194 Otagiri H, Fukuda Y, Nakano I, Katano Y, Toyoda H, Yokozaki S, Hayashi K, Hayakawa T, Fukuda Y, Kinoshita M, Takamatsu J. Evaluation of a new assay for hepatitis C virus genotyping and viral load determination in patients with chronic hepatitis C. Journal of Virological Methods 2002;103:137-43. [DOI: 10.1016/s0166-0934(02)00018-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
195 Morishima C, Gretch DR. CLINICAL USE OF HEPATITIS C VIRUS TESTS FOR DIAGNOSIS AND MONITORING DURING THERAPY. Clinics in Liver Disease 1999;3:717-40. [DOI: 10.1016/s1089-3261(05)70235-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
196 Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol. 2002;40:768-773. [PMID: 11880391 DOI: 10.1128/jcm.40.3.768-773.2002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
197 Farci P. Hepatitis C virus. The importance of viral heterogeneity. Clin Liver Dis. 2001;5:895-916. [PMID: 11685800 DOI: 10.1016/s1089-3261(05)70200-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
198 Davis GL. Treatment of chronic hepatitis C: impact of combination therapy. Curr Gastroenterol Rep 1999;1:9-14. [PMID: 10980920 DOI: 10.1007/s11894-999-0080-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
199 Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, Ihori M, Hirota K, Ono N, Kuroda H. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol. 2000;33:313-322. [PMID: 10952250 DOI: 10.1016/s0168-8278(00)80373-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
200 Loftis JM, Morasco BJ, Menasco D, Fuchs D, Strater M, Hauser P. Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C. Open Infect Dis J 2010;4:132-41. [PMID: 21151716 DOI: 10.2174/1874279301004010132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
201 Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat. 2000;7:250-257. [PMID: 10886533 DOI: 10.1046/j.1365-2893.2000.00233.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 1.8] [Reference Citation Analysis]
202 Yoho RA, Cruz LL, Mazaheri R, Cruz AT. Hepatitis C: A Review: . Plastic and Reconstructive Surgery 2003;112:597-605. [DOI: 10.1097/01.prs.0000070701.04809.95] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Salmerón J, De Rueda PM, Ruiz-Extremera A, Casado J, Huertas C, Bernal Mdel C, Rodríguez L, Palacios A. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C. Dig Dis Sci 2006;51:960-7. [PMID: 16758308 DOI: 10.1007/s10620-006-9347-2] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
204 McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling MH, Garaud JJ, Albrecht JK, Patel K. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002;35:688-693. [PMID: 11870385 DOI: 10.1053/jhep.2002.31870] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 4.7] [Reference Citation Analysis]
205 Songsivilai S, Kanistanon D, Dharakul T. A serotyping assay for hepatitis C virus in Southeast Asia. Clin Diagn Lab Immunol 1998;5:737-9. [PMID: 9729545 DOI: 10.1128/CDLI.5.5.737-739.1998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
206 Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13:223-235. [PMID: 10755999 DOI: 10.1128/cmr.13.2.223-235.2000] [Cited by in Crossref: 244] [Cited by in F6Publishing: 10] [Article Influence: 11.6] [Reference Citation Analysis]
207 Norton BL, Voils CI, Timberlake SH, Hecker EJ, Goswami ND, Huffman KM, Landgraf A, Naggie S, Stout JE. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis 2014;14:74. [PMID: 24512462 DOI: 10.1186/1471-2334-14-74] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
208 Rosenberg P. Hepatitis C: A Hepatologist's Approach to an Infectious Disease. CLIN INFECT DIS 2001;33:1728-32. [DOI: 10.1086/323128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
209 Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36:S152-S160. [PMID: 12407589 DOI: 10.1002/hep.1840360720] [Cited by in Crossref: 119] [Cited by in F6Publishing: 87] [Article Influence: 6.3] [Reference Citation Analysis]
210 Moreno-monteagudo JA, Castro A, De Pedro A, Lorenzo JA, Fernández-bermejo M, Lopez S, García-buey L, Borque MJ, Pedreira JD, Moreno-otero R. Interferon-α plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers: COMBINED TREATMENT FOR HEPATITIS C RELAPSERS. Alimentary Pharmacology & Therapeutics 2002;16:243-9. [DOI: 10.1046/j.1365-2036.2002.01162.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
211 El-Awady MK, Abdel Rahman MM, Ismail SM, Amr KS, Omran M, Mohamed SA. Prediction of relapse after interferon therapy in hepatitis C virus-infected patients by the use of triple assay. J Gastroenterol Hepatol. 2003;18:68-73. [PMID: 12519227 DOI: 10.1046/j.1440-1746.2003.02919.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
212 Depraetere S, Van Kerschaever E, Van Vlierberghe H, Elewaut A, Brouwer JT, Niesters HG, Schalm SW, Maertens G, Leroux-roels G. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. J Med Virol 2000;60:126-32. [DOI: 10.1002/(sici)1096-9071(200002)60:2<126::aid-jmv4>3.0.co;2-l] [Cited by in Crossref: 16] [Article Influence: 0.8] [Reference Citation Analysis]
213 Sagrini E, Ardoino I, Marano G, Gianstefani A, Orlandini A, Sebastiani G, Donati G, Cucchetti A, Pelosi G, Ferrari C, Alberti A, Biganzoli E, Piscaglia F, Bolondi L. Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. European Journal of Gastroenterology & Hepatology 2013;25:1385-95. [DOI: 10.1097/meg.0b013e328363e29d] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
214 Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. J Med Virol 1999;58:353-8. [DOI: 10.1002/(sici)1096-9071(199908)58:4<353::aid-jmv6>3.0.co;2-c] [Cited by in Crossref: 51] [Article Influence: 2.3] [Reference Citation Analysis]
215 Ahmed OA, Kaisar HH, Badawi R, Hawash N, Samir H, Shabana SS, Fouad MHA, Rizk FH, Khodeir SA, Abd-Elsalam S. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 2018;11:295-8. [PMID: 29535545 DOI: 10.2147/IDR.S153060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
216 Fontana RJ, Israel J, Leclair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, Bonkovsky HL. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial: Iron Reduction Before and During Interferon Therapy of Chronic Hepatitis C: Results of a Multicenter, Randomized, Controlled Trial. Hepatology 2000;31:730-6. [DOI: 10.1002/hep.510310325] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 6.3] [Reference Citation Analysis]